A new law in Russia allows to create and execute a blacklist of so called “undesirable” organizations, whose principals can be sentenced to a fine or prison. Dmitry Zimin - Russia’s only private funder of scientific research – has announced a closure of his Dynasty Foundation after being labeled by t...
Read more
Russian biotechnology sector as a part of central European region is still underfunded. However, despite political issues, it has a great potential for development with several leading companies shaping the regional market. Irina Gennadyevna, Public Relations Manager at BIOCAD, describes the company ...
Read more
Petrov Research Institute of Oncology is one of the oldest such places in Russia. Its broad experience in cancer research interested one of the biggest players on pharma market - Astra Zeneca....
Read more
On January 7th NewVac, the subsidiary of ChemRar High Tech Center (a Russian non-governmental R&D center for life sciences), announced a co-license agreement with Janssen Pharmaceutica, a pharmaceutical company of Johnson & Johnson. According to the contract NewVacs receives the exclusive rights for...
Read more
Lately, increased activity in clinical trials could be observed in the Russian market. Only in the second quarter of 2012 275 trials were approved, which is a 44% jump from the same period in 2011. According to Vladimir Putin words, Russia aims for being a super power in the sector of biomedicine and...
Read more
Newly developed drugs must be controlled in terms of efficiency and safety. At this step clinical trials are inevitable. They account for the biggest and also the longest part of total cost connected with introduction of new pharmaceuticals to the market. It is estimated that the global market of cli...
Read more